Eficacia de la tirzepatida en pacientes con diabetes mellitus tipo 2 y obesidad: un innovador fármaco dual
Resumen
La Tirzepatida creada por Eli Lilly and Company, es el primer agonista dual del receptor del polipéptido insulinotrópico dependiente de glucosa o GIP y del péptido similar al glucagón-1 o GLP-1. Se aplica una sola vez a la semana e integra las acciones de ambas incretinas en una única molécula. Las investigaciones clínicas de Tirzepatida demuestran una eficacia importante y prometedora para la reducción de peso corporal y glucosa en diabetes mellitus 2, mostrando superioridad a otros fármacos GLP-1. Objetivos: Describir la eficacia de la Tirzepatida en pacientes con Diabetes Mellitus 2 y obesidad. Métodos: Se realizó una revisión bibliográfica para analizar la eficacia y beneficios de la Tirzepatida especialmente en referência al tratamiento de la Diabetes Mellitus de tipo 2 y la obesidad. Conclusiones: Las reducciones en el nivel de hemoglobina glicosilada y el peso corporal observados con Tirzepatida fueron consistentes en los resultados de los ensayos clínicos. Estos resultados fueron dependiente a la dosis, es decir que mayor dosis mayores efectos beneficios en comparación con otros fármacos. Se verificó una buena seguridad y tolerancia al fármaco en diferentes poblaciones pudiendo llegar a ser una de las primeras alternativas farmacológicas para el tratamiento para estas patologías.
Descargas
Citas
Ros Pérez M, Medina-Gómez G. Obesidad, adipogénesis y resistencia a la insulina. Endocrinología y Nutrición. 1;58(7):360–9.
Esther D la calle de la villa. La Tirzepatida. Ampliando el espectro del tratamiento de la diabetes tipo 2. Revista Diabetes. 2022; 2(2).
Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine. 2022 Feb 24;28(3):591–8. https://doi.org/10.1038/s41591-022-01707-4
Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2020 Nov ;106(2):388–96. https://doi.org/10.1210/clinem/dgaa863
Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 2020 Apr 14;43(6):1352–5. https://doi.org/10.2337/dc19-1892
Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials. Pharmaceuticals. 2021 Sep 28; 14(10):991. https://doi.org/10.3390/ph14100991
Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, et al. The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2020 Sep 15; 22(12):2451–9. https://doi.org/10.1111/dom.14174
Chavda V, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 5;27(13):4315.
Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Therapy. 2020 Dec 15;12(1):143–57. https://doi.org/10.1007/s13300-020-009810
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018; 18:3–14.
Ohwaki K, Furihata K, Mimura M, Oura T, Imaoka T. 1024-P: effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM. Diabetes. 2019;68
Frías JP, Nauck MA, Van J, Benson C, Bray R, Cui X, et al Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–93.
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021 Jul;398(10295):143–55.
Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2022 Feb 8;327(6):534. https://doi.org/10.1001/jama.2022.0078
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022 Jul 21;387(3):205–16. https://doi.org/10.1056/nejmoa2206038
Nauck MA, D‘Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology. 2022 Sep 1; 21(1). https://doi.org/10.1186/s12933-022-01604-7
Inoue H, Tamaki Y, Kashihara Y, Muraki S, Kakara M, Hirota T, et al. Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis. British Journal of Clinical Pharmacology. 2018 Dec 6;85(2):393–402. https://doi.org/10.1111/bcp.13807
Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, et al. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacological Research. 2021 Sep; 17(1):105-782. https://doi.org/10.1016/j.phrs.2021.105782
Frías JP, Davies M, Rosenstock J, Pérez Manghi F, Fernández Landó L, Bergman B, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Eng J Med. 2021 Jun 25;385(6):503–15.
Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Molecular Metabolism. 2021 Apr;46(1):1010–90.
Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17;65(8):1251–61. https://doi.org/10.1007/s00125-022-05715-4
Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 5; 27(13):4315. https://doi.org/10.3390/molecules27134315
Urva S, Quinlan T, Landry J, Martin J, Loghin C. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics. 2021 Mar 29;60(8):104-959.
Lempesis I, Liu J, Dalamaga M. The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. Metabolism Open. 2022 Dec 1;16(46):100–220.
Derechos de autor 2023 María Gracia Machado Fernández ;Etsa Robinson Tsenkush Chamik; Victor Manuel Largo Rivera; María Cristina Robles Delgado; Angie Carolina Sarango Feijoó ; Karina Fernanda Pucha Aguinsaca
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.jpg)
